Stay updated on Pembrolizumab as AML Post-Remission Treatment Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab as AML Post-Remission Treatment Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab as AML Post-Remission Treatment Clinical Trial page

  1. Check
    3 days ago
    Change Detected
    Summary
    The site revision identifier in the footer changes from v3.7.1 to v3.7.2 on the 403 error page.
    Difference
    0.2%
    Check dated 2026-10-18T22:21:36.000Z thumbnail image
  2. Check
    10 days ago
    Change Detected
    Summary
    The footer revision label was updated from v3.7.0 to v3.7.1.
    Difference
    0.2%
    Check dated 2026-10-11T22:23:18.000Z thumbnail image
  3. Check
    17 days ago
    No Change Detected
  4. Check
    31 days ago
    Change Detected
    Summary
    The page now shows a 403 Forbidden error instead of the study record content for NCT02708641, indicating access is blocked. This reflects an access/error condition rather than a content update.
    Difference
    18%
    Check dated 2026-09-20T22:40:34.000Z thumbnail image
  5. Check
    52 days ago
    Change Detected
    Summary
    The page revision label updated from v3.6.5 to v3.6.6, indicating a minor template/backend update. No study content or data are changed.
    Difference
    0.1%
    Check dated 2026-08-30T15:46:22.000Z thumbnail image
  6. Check
    74 days ago
    Change Detected
    Summary
    Revision: v3.6.5 was added to the page, indicating an updated version of the study record display. Older study-record items and documents (e.g., PDFs, past posting dates, and related links) were removed from the page.
    Difference
    17%
    Check dated 2026-08-09T00:16:52.000Z thumbnail image
  7. Check
    88 days ago
    Change Detected
    Summary
    Revision tag updated from v3.6.3 to v3.6.4, indicating a software release. There are no visible changes to the study content or page functionality beyond the metadata.
    Difference
    0.1%
    Check dated 2026-07-25T17:14:48.000Z thumbnail image

Stay in the know with updates to Pembrolizumab as AML Post-Remission Treatment Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab as AML Post-Remission Treatment Clinical Trial page.